Opendata, web and dolomites

Capsulight

The first ingestible capsule for eradicating Helicobacter pylori infection through photodynamic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Capsulight project word cloud

Explore the words cloud of the Capsulight project. It provides you a very rough idea of what is the project "Capsulight" about.

proton    resistance    advantages    hospitalization    agent    safety    florence    probiomedica    50    attributable    healthcare    off    vitro    savings    97    infection    presented    anna    miniaturization    treatment    photobiology    stomach    market    therapies    carcinogen    ingestible    world    power    inhibitor    mass    diagnosed    sant    light    reducing    optimize    capsules    rate    once    pylori    clinical    device    assumption    population    specialized    economic    eradicated    70    national    ce    biopsies    photodynamic    capsulight    efficacy    usually    tests    antibiotic    drug    preliminary    helicobacter    pump    robotics    patented    posology    despite    reaching    mix    infected    cured    scuola    drugs    biopsy    eradicate    medicine    showed    university    diagnostic    first    endoscopic    superiore    90    cancers    possibility    unparalleled    microbiology    gastroenterology    countries    mark    unfortunately    spin    undergo    bacterium    pharmacological    gastric    cycles    therapy    secondary    capsule    intragastric    validation    centers    killing    30   

Project "Capsulight" data sheet

The following table provides information about the project.

Coordinator
PROBIOMEDICA SRL 

Organization address
address: VIA DI BELLOSGUARDO 2 ROSSO
city: FIRENZE
postcode: 50124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.probiomedica.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROBIOMEDICA SRL IT (FIRENZE) coordinator 50˙000.00

Map

 Project objective

Helicobacter pylori (H. pylori) is a bacterium of the stomach which affects on average 50% of the world population, reaching up to 70% in some European Countries. Once it is diagnosed, it has to be eradicated, since it is a carcinogen agent and around 90% of all gastric cancers can be attributable to its infection. The only available treatment is a pharmacological therapy based on the assumption of proton-pump inhibitor and a mix of 2-3 antibiotic drugs. Unfortunately, due to increasing antibiotic resistance, up to 30% of the affected population cannot be cured, despite several cycles of antibiotic therapy and usually endoscopic biopsy to determine antibiotic-resistance. Probiomedica is a spin-off of the University of Florence and Scuola Superiore Sant’Anna specialized in photobiology and robotics applied to medicine, which has developed and patented CapsuLight, the first ingestible capsule able to eradicate H. Pylori infection through intragastric photodynamic therapy, that is through the power of light. The device is based on the established technology and safety of endoscopic capsules for diagnostic use, and our preliminary in vitro tests showed 97% efficacy in killing the bacterium. The advantages for infected population are unparalleled: the possibility to eradicate the bacterium for those who cannot be cured due to antibiotic resistance (our first target market); the higher efficacy rate, no side effects due to antibiotic cycles, and easy posology for all the infected population (secondary market). CapsuLight will also provide high economic savings to National Healthcare Systems, by reducing drug therapies cycles and endoscopic biopsies and related costs for hospitalization. Probiomedica has already presented the product to several gastroenterology and microbiology centers and will optimize the capsule design for further miniaturization and mass production, and to undergo the necessary clinical validation for getting the CE mark during the Phase 2 project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAPSULIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAPSULIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More